GR1802 is named as an intervention in 4 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 3. The lead sponsor is Genrix (Shanghai) Biopharmaceutical Co., Ltd. The most-studied condition is Allergic Rhinitis, Seasonal.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
NCT07154342 · ClinicalTrials.gov ↗ · Allergic Rhinitis, Seasonal
|
Phase 3 | Recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | China |
|
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
NCT07199257 · ClinicalTrials.gov ↗ · Allergic Rhinitis, Seasonal
|
Phase 3 | Not yet open | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | China |
|
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
NCT06516302 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps
|
Phase 3 | Active, closed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | China |
|
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426 · ClinicalTrials.gov ↗ · Allergic Rhinitis
|
Phase 2 | Active, closed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 4 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name GR1802 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 4 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Genrix (Shanghai) Biopharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how GR1802 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how GR1802 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GR1802 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.